Looking Into Viveve Medical's Return On Invested Capital

Benzinga Pro data, Viveve Medical VIVE reported Q4 sales of $1.71 million. Earnings fell to a loss of $6.33 million, resulting in a 8.02% decrease from last quarter. Viveve Medical collected $1.62 million in revenue during Q3, but reported earnings showed a $5.86 million loss.

What Is Return On Invested Capital?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q4, Viveve Medical posted an ROIC of -21.68%.

Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Viveve Medical posted an ROIC of -21.68%.

It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

For Viveve Medical, a negative ROIC ratio of -21.68% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Viveve Medical reported Q4 earnings per share at $-0.72/share, which did not meet analyst predictions of $-0.59/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.